18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Primary Purpose
Cigarette Smoker, Current Smoker, Former Smoker
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Computed Tomography
Fludeoxyglucose F-18
Fluorine F 18 L-glutamate Derivative BAY94-9392
Positron Emission Tomography
Sponsored by
About this trial
This is an interventional diagnostic trial for Cigarette Smoker
Eligibility Criteria
Inclusion Criteria:
- Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
- Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
- Current or former cigarette smoker, with >= 20 pack years
- Documented informed consent
Exclusion Criteria:
- History or previous diagnosis of lung cancer
- Cancer diagnosis within the last 5 years
- Pregnant or nursing
Sites / Locations
- Stanford Cancer Institute Palo AltoRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)
Arm Description
Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
Outcomes
Primary Outcome Measures
Fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) specificity for malignant lung nodules
18F-FSPG accumulation in lung nodules will be assessed. The observed FSPG specificity will be assessed against a fixed value of 75%.
Secondary Outcome Measures
Improved performance of prediction model for lung nodules
Improved performance is defined as a p < 0.05 increase in the C statistic determined using DeLong test for correlated receiver operating characteristic (ROC) curves.
Full Information
NCT ID
NCT03824535
First Posted
January 29, 2019
Last Updated
March 6, 2023
Sponsor
Andrei Iagaru
Collaborators
Canary Foundation, Boston University
1. Study Identification
Unique Protocol Identification Number
NCT03824535
Brief Title
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Official Title
18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 4, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Andrei Iagaru
Collaborators
Canary Foundation, Boston University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.
Detailed Description
PRIMARY OBJECTIVES:
I. Comparison of fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) accumulation with fludeoxyglucose F-18 (18F-FDG) accumulation to assess whether (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate (18F-FSPG)-PET is better at discriminating between benign and malignant nodules.
SECONDARY OBJECTIVES:
I. To develop and validate early lung cancer detection biomarkers that would directly impact the growing need to integrate imaging and non-invasive molecular diagnostics for indeterminate pulmonary nodules and allow physicians to avoid unnecessary invasive procedures in patients with benign lung disease.
OUTLINE:
Patients receive 18F-FSPG intravenously (IV) and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG and undergo a second PET/CT scan over 30-60 minutes.
After completion of study, patients are followed up within 24-72 hours.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cigarette Smoker, Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Pulmonary Nodule
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)
Arm Type
Experimental
Arm Description
Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
Intervention Type
Procedure
Intervention Name(s)
Computed Tomography
Other Intervention Name(s)
CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography
Intervention Description
Undergo PET/CT
Intervention Type
Drug
Intervention Name(s)
Fludeoxyglucose F-18
Other Intervention Name(s)
18-FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18
Intervention Description
Given IV
Intervention Type
Drug
Intervention Name(s)
Fluorine F 18 L-glutamate Derivative BAY94-9392
Other Intervention Name(s)
(S)-4-(3-18F-fluoropropyl)-L-glutamic Acid, 18F-FSPG, BAY94-9392
Intervention Description
Given IV
Intervention Type
Procedure
Intervention Name(s)
Positron Emission Tomography
Other Intervention Name(s)
Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Intervention Description
Undergo PET/CT
Primary Outcome Measure Information:
Title
Fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) specificity for malignant lung nodules
Description
18F-FSPG accumulation in lung nodules will be assessed. The observed FSPG specificity will be assessed against a fixed value of 75%.
Time Frame
Up to 5 years
Secondary Outcome Measure Information:
Title
Improved performance of prediction model for lung nodules
Description
Improved performance is defined as a p < 0.05 increase in the C statistic determined using DeLong test for correlated receiver operating characteristic (ROC) curves.
Time Frame
Up to 5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
Current or former cigarette smoker, with >= 20 pack years
Documented informed consent
Exclusion Criteria:
History or previous diagnosis of lung cancer
Cancer diagnosis within the last 5 years
Pregnant or nursing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mahima Goel
Phone
650-723-0371
Email
mahimag@stanford.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carina M Aparici
Organizational Affiliation
Stanford Cancer Institute Palo Alto
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford Cancer Institute Palo Alto
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mahima Goel
Phone
650-723-0371
Email
mahimag@stanford.edu
First Name & Middle Initial & Last Name & Degree
Carina M Aparici, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
We'll reach out to this number within 24 hrs